Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New radiation technique aims to protect lungs and kidneys in scleroderma stem cell transplants

NCT ID NCT04380831

First seen Apr 01, 2026 · Last updated Jun 22, 2026 · Updated 10 times

Summary

This early-phase trial tests a more precise form of total body radiation (IMRT) combined with the chemotherapy drug cyclophosphamide before a stem cell transplant in 15 people with severe systemic sclerosis (scleroderma). The goal is to see if this approach is safe and can reduce radiation exposure to the lungs and kidneys compared to standard methods. The study focuses on feasibility and side effects, not yet on curing the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLERODERMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • City of Hope Medical Center

    RECRUITING

    Duarte, California, 91010, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Cyclophosphamide (chemotherapy) and total body irradiation (radiation therapy)

What this could lead to

If it works, this could lead to a safer stem cell transplant approach for severe scleroderma, reducing damage to lungs and kidneys.

What could go wrong

This is a very early, small pilot study with only 15 people, so results may not apply widely. The treatment involves strong chemo and radiation, which carry serious risks like infection and organ damage.

Conditions

The condition(s) this trial relates to.

systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.